Response prediction of third-line cetuximab-based therapy for patients with metastatic colorectal cancer using Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT)

Not Applicable

Recruiting

• Conditions: Metastatic colorectal cancer receiving third-line therapy with cetuximab; Cancer - Bowel - Back passage (rectum) or large bowel (colon)

• Registration Number: ACTRN12612000052831
• Lead Sponsor: Chang Gung Memorial Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-01-11
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. at least one measurable lesion as defined by RECIST criteria.
2. received both the irinotecan-based and oxaliplatin-based regimens.
3. must have tumor specimen determined to have wild-type K-ras.

Exclusion Criteria

1. History of another primary malignancy less than 3 years
2. Prior treatment with cetuximab or panitumumab

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Predictive value of response evaluation (including changes of SUV and MTV values) by FDG PET/CT for progression-free survival (assessed by RECIST criteria 1.1)[All participants be assessed for progression-free survival every 3 months by CT scans (RECIST criteria 1.1) up to one year after enrollment]

Secondary Outcome Measures

Name	Time	Method
Predictive value of response evaluation (including changes of SUV and MTV values) by FDG PET/CT for overall survival[All participants be assessed for overall survival up to two years after enrolment]